Literature DB >> 20367525

Brimonidine for glaucoma.

Mamun Q Rahman1, Kanna Ramaesh, Donald M I Montgomery.   

Abstract

IMPORTANCE OF THE FIELD: Brimonidine is a drug used in the management of glaucoma throughout the world and is the most modern alpha(2)-adrenoceptor agonist available. This review comprehensively discusses the use of brimonidine for glaucoma. AREAS COVERED IN THIS REVIEW: A historical insight into the development of selective adrenergic glaucoma drugs is given, followed by a description of the mechanisms of action and a discussion of the main clinical trials investigating clinical applications. The safety of brimonidine is evaluated, and our expert opinion is provided on how brimonidine is used in our clinical practice. The most relevant literature on the role of brimonidine in glaucoma is discussed. WHAT THE READER WILL GAIN: A clear understanding of the role of brimonidine for glaucoma treatment, with an explanation of its efficacy, limitations and use in clinical practice. TAKE HOME MESSAGE: Brimonidine is an effective drug for lowering intraocular pressure. It has potentially serious systemic effects in children, in whom it is contraindicated. Its use in adults is limited by its ocular side effects such as allergy. Brimonidine is, however, an important part of the range of intraocular pressure lowering drugs available to prescribers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367525     DOI: 10.1517/14740331003709736

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  12 in total

1.  Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.

Authors:  J Fowler; M Jarratt; A Moore; K Meadows; A Pollack; M Steinhoff; Y Liu; M Leoni
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

2.  Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

3.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

4.  Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily.

Authors:  Elad Moisseiev; Shimon Kurtz; Moshe Lazar; Gabi Shemesh
Journal:  Clin Ophthalmol       Date:  2013-06-25

5.  A Single Drop in the Eye - Effects on the Whole Body?

Authors:  Anu Vaajanen; Heikki Vapaatalo
Journal:  Open Ophthalmol J       Date:  2017-10-31

6.  Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.

Authors:  Eugene McLaurin; Megan E Cavet; Paul J Gomes; Joseph B Ciolino
Journal:  Optom Vis Sci       Date:  2018-03       Impact factor: 1.973

7.  Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.

Authors:  Stacey L Ackerman; Gail L Torkildsen; Eugene McLaurin; Jason L Vittitow
Journal:  Clin Exp Optom       Date:  2018-12-07       Impact factor: 2.742

8.  Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury.

Authors:  Xiaotong Lou; Yuanyuan Hu; Hong Zhang; Jia Liu; Yin Zhao
Journal:  J Nanobiotechnology       Date:  2021-12-20       Impact factor: 10.435

9.  Prophylactic effect of brimonidine to minimize the incidence of subconjunctival hemorrhage in the early postoperative period after 23G pars plana vitrectomy.

Authors:  Mari Carmen Desco; Julio Cesar Molina Martín; Jorge Mataix-Boronat; Isabel Pascual-Camps; Elena Palacios-Pozo; Marisa Barón-García; David P Piñero; Amparo Navea-Tejerina
Journal:  Ther Adv Ophthalmol       Date:  2021-10-05

10.  The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients.

Authors:  Toyoaki Tsumura; Keiji Yoshikawa; Tairo Kimura; Hirotaka Suzumura; Miwako Kawashima; Mami Nanno; Kiyotaka Ishijima; Ryuji Takeda
Journal:  Clin Ophthalmol       Date:  2014-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.